Physicians' Academy for Cardiovascular Education

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona

Video navigation menu

  • LDL-c in the pathophysiology of atherosclerosis 2:42
  • Once a fatty streak lesion is present, plaque inflammation develops and the plaque progresses 5:04
  • Cholesterol crystals characterize mature plaques 7:14
  • How did prevention trial interventions impact on the pathogenesis of atherosclerosis? 8:33
  • Potential mechanisms of how LDL-c lowering regresses and stabilizes plaques 11:56
  • Evidence accumulates: LDL is causal in ASCVD  13:30

Educational information

The educational objectives of the symposium were to:


John Chapman is Research Professor at the Pierre and Marie Curie University, and Director Emeritus of the National Institute for Health and Medical Research (INSERM) at the Pitié-Salpêtrière University Hospital in Paris, France

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).


This symposum was supported by unrestricted educational grants provided by Amgen and Sanofi-Regeneron

Download abstract and key slides View and download slides


This is available as accredited online CME for members. Click the button below to enroll:

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: